REPLIMUNE GROUP, INC. Long-Term Debt, Maturity, Year Five
REPLIMUNE GROUP, INC. (REPL) had Long-Term Debt, Maturity, Year Five of $2.92 million as of 2019-12-31, per its 10-Q filed 2020-02-13.
Discontinued › Notes › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Four and Five
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive · last filed 2020-02-13
- 2019-12-31: Long-Term Debt, Maturity, Year Five $2.92M.
- 2019-09-30: Long-Term Debt, Maturity, Year Five $2.92M.
| Period end | Long-Term Debt, Maturity, Year Five |
|---|---|
| 2019-12-31 | $2.92M 10-Q · filed 2020-02-13 |
| 2019-09-30 | $2.92M 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |